Reference
Bernard-Valnet R, et al. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Multiple Sclerosis and Related Disorders 25: 216-218, Oct 2018. Available from: URL: http://doi.org/10.1016/j.msard.2018.08.006 - France
Rights and permissions
About this article
Cite this article
Alemtuzumab/fingolimod/methylprednisolone. Reactions Weekly 1719, 20 (2018). https://doi.org/10.1007/s40278-018-51575-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-51575-5